Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry

Joshua Schulman-Marcus; Bríain T. Hartaigh; Ashley E. Giambrone; Heidi Gransar; Valentina Valenti; Daniel S. Berman; Matthew J. Budoff; Stephan Achenbach; Mouaz Al-Mallah; Daniele Andreini; Filippo Cademartiri; Tracy Q. Callister; Hyuk Jae Chang; Kavitha Chinnaiyan; Benjamin J.W. Chow; Ricardo Cury; Augustin Delago; Martin Hadamitzky; Joerg Hausleiter; Gudrun Feuchtner; Yong Jin Kim; Philipp A. Kaufmann; Jonathon Leipsic; Fay Y. Lin; Erica Maffei; Gianluca Pontone; Gilbert Raff; Leslee J. Shaw; Todd C. Villines; Allison Dunning; James K. Min

doi:10.1016/j.atherosclerosis.2014.11.007

Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry

Joshua Schulman-Marcus, Bríain T. Hartaigh, Ashley E. Giambrone, Heidi Gransar, Valentina Valenti, Daniel S. Berman, Matthew J. Budoff, Stephan Achenbach, Mouaz Al-Mallah, Daniele Andreini, Filippo Cademartiri, Tracy Q. Callister, Hyuk Jae Chang, Kavitha Chinnaiyan, Benjamin J.W. Chow, Ricardo Cury, Augustin Delago, Martin Hadamitzky, Joerg Hausleiter, Gudrun FeuchtnerYong Jin Kim, Philipp A. Kaufmann, Jonathon Leipsic, Fay Y. Lin, Erica Maffei, Gianluca Pontone, Gilbert Raff, Leslee J. Shaw, Todd C. Villines, Allison Dunning, James K. Min

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Objective: This study sought to determine the correlation between baseline cardiac medications and cardiovascular outcomes in patients with obstructive coronary artery disease (CAD) diagnosed by coronary computed tomographic angiography (CCTA). Methods: 1637 patients (mean age 64.8±10.2 years, 69.6% male) with obstructive CAD from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registry were followed over the course of three years. Obstructive CAD was defined as a ≥50% stenosis in an epicardial vessel. Medications analyzed included statins, aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Using Cox proportional-hazards models, we calculated the hazard ratio (HR) with 95% confidence intervals (95% CIs) for incident major adverse cardiovascular events (MACE), defined as death, acute coronary syndrome, or myocardial infarction. Results: At the time of CCTA, 59%, 54%, 40%, and 46% of patients were using statins, aspirin, beta-blockers, and ACE inhibitors or ARBs, respectively. Statins were associated with a 43% (95% CI=0.38-0.87, p=0.008) lower adjusted risk of MACE. Following adjustment, aspirin, beta-blockers, ACE inhibitors and ARBs did not attenuate the risk of MACE. When restricted to patients with multivessel obstructive CAD, only statins were associated with lower risk of MACE. Conclusion: In patients with obstructive CAD by CCTA, the baseline use of statins was associated with improved clinical outcomes. Other cardiac medications-including aspirin, beta-blockers, ACE inhibitors, and ARBs-were not associated with reduced risk of MACE.

Original language	English
Pages (from-to)	119-125
Number of pages	7
Journal	Atherosclerosis
Volume	238
Issue number	1
DOIs	https://doi.org/10.1016/j.atherosclerosis.2014.11.007
Publication status	Published - 2015 Jan 1

Bibliographical note

Funding Information:
Research reported in this publication was supported by the Heart Lung and Blood Institute of the National institutes of Health (Bethesda, Maryland) under award number R01 HL115150. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was supported by Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning(MSIP) (2012027176). This study was also funded, in part, by a generous gift from the Dalio Institute of Cardiovascular Imaging (New York, NY) and the Michael Wolk Foundation (New York, NY).

Publisher Copyright:
© 2014 Elsevier Ireland Ltd.

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.atherosclerosis.2014.11.007

Cite this

Schulman-Marcus, J., Hartaigh, B. T., Giambrone, A. E., Gransar, H., Valenti, V., Berman, D. S., Budoff, M. J., Achenbach, S., Al-Mallah, M., Andreini, D., Cademartiri, F., Callister, T. Q., Chang, H. J., Chinnaiyan, K., Chow, B. J. W., Cury, R., Delago, A., Hadamitzky, M., Hausleiter, J., ... Min, J. K. (2015). Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry. Atherosclerosis, 238(1), 119-125. https://doi.org/10.1016/j.atherosclerosis.2014.11.007

@article{10b346de08e64da3aa522194e2e30ada,

title = "Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry",

abstract = "Objective: This study sought to determine the correlation between baseline cardiac medications and cardiovascular outcomes in patients with obstructive coronary artery disease (CAD) diagnosed by coronary computed tomographic angiography (CCTA). Methods: 1637 patients (mean age 64.8±10.2 years, 69.6% male) with obstructive CAD from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registry were followed over the course of three years. Obstructive CAD was defined as a ≥50% stenosis in an epicardial vessel. Medications analyzed included statins, aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Using Cox proportional-hazards models, we calculated the hazard ratio (HR) with 95% confidence intervals (95% CIs) for incident major adverse cardiovascular events (MACE), defined as death, acute coronary syndrome, or myocardial infarction. Results: At the time of CCTA, 59%, 54%, 40%, and 46% of patients were using statins, aspirin, beta-blockers, and ACE inhibitors or ARBs, respectively. Statins were associated with a 43% (95% CI=0.38-0.87, p=0.008) lower adjusted risk of MACE. Following adjustment, aspirin, beta-blockers, ACE inhibitors and ARBs did not attenuate the risk of MACE. When restricted to patients with multivessel obstructive CAD, only statins were associated with lower risk of MACE. Conclusion: In patients with obstructive CAD by CCTA, the baseline use of statins was associated with improved clinical outcomes. Other cardiac medications-including aspirin, beta-blockers, ACE inhibitors, and ARBs-were not associated with reduced risk of MACE.",

author = "Joshua Schulman-Marcus and Hartaigh, {Br{\'i}ain T.} and Giambrone, {Ashley E.} and Heidi Gransar and Valentina Valenti and Berman, {Daniel S.} and Budoff, {Matthew J.} and Stephan Achenbach and Mouaz Al-Mallah and Daniele Andreini and Filippo Cademartiri and Callister, {Tracy Q.} and Chang, {Hyuk Jae} and Kavitha Chinnaiyan and Chow, {Benjamin J.W.} and Ricardo Cury and Augustin Delago and Martin Hadamitzky and Joerg Hausleiter and Gudrun Feuchtner and Kim, {Yong Jin} and Kaufmann, {Philipp A.} and Jonathon Leipsic and Lin, {Fay Y.} and Erica Maffei and Gianluca Pontone and Gilbert Raff and Shaw, {Leslee J.} and Villines, {Todd C.} and Allison Dunning and Min, {James K.}",

note = "Funding Information: Research reported in this publication was supported by the Heart Lung and Blood Institute of the National institutes of Health (Bethesda, Maryland) under award number R01 HL115150. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was supported by Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning(MSIP) (2012027176). This study was also funded, in part, by a generous gift from the Dalio Institute of Cardiovascular Imaging (New York, NY) and the Michael Wolk Foundation (New York, NY). Publisher Copyright: {\textcopyright} 2014 Elsevier Ireland Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1016/j.atherosclerosis.2014.11.007",

language = "English",

volume = "238",

pages = "119--125",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Schulman-Marcus, J, Hartaigh, BT, Giambrone, AE, Gransar, H, Valenti, V, Berman, DS, Budoff, MJ, Achenbach, S, Al-Mallah, M, Andreini, D, Cademartiri, F, Callister, TQ, Chang, HJ, Chinnaiyan, K, Chow, BJW, Cury, R, Delago, A, Hadamitzky, M, Hausleiter, J, Feuchtner, G, Kim, YJ, Kaufmann, PA, Leipsic, J, Lin, FY, Maffei, E, Pontone, G, Raff, G, Shaw, LJ, Villines, TC, Dunning, A & Min, JK 2015, 'Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry', Atherosclerosis, vol. 238, no. 1, pp. 119-125. https://doi.org/10.1016/j.atherosclerosis.2014.11.007

Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry. / Schulman-Marcus, Joshua; Hartaigh, Bríain T.; Giambrone, Ashley E. et al.
In: Atherosclerosis, Vol. 238, No. 1, 01.01.2015, p. 119-125.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography

T2 - Results from the multicenter CONFIRM registry

AU - Schulman-Marcus, Joshua

AU - Hartaigh, Bríain T.

AU - Giambrone, Ashley E.

AU - Gransar, Heidi

AU - Valenti, Valentina

AU - Berman, Daniel S.

AU - Budoff, Matthew J.

AU - Achenbach, Stephan

AU - Al-Mallah, Mouaz

AU - Andreini, Daniele

AU - Cademartiri, Filippo

AU - Callister, Tracy Q.

AU - Chang, Hyuk Jae

AU - Chinnaiyan, Kavitha

AU - Chow, Benjamin J.W.

AU - Cury, Ricardo

AU - Delago, Augustin

AU - Hadamitzky, Martin

AU - Hausleiter, Joerg

AU - Feuchtner, Gudrun

AU - Kim, Yong Jin

AU - Kaufmann, Philipp A.

AU - Leipsic, Jonathon

AU - Lin, Fay Y.

AU - Maffei, Erica

AU - Pontone, Gianluca

AU - Raff, Gilbert

AU - Shaw, Leslee J.

AU - Villines, Todd C.

AU - Dunning, Allison

AU - Min, James K.

N1 - Funding Information: Research reported in this publication was supported by the Heart Lung and Blood Institute of the National institutes of Health (Bethesda, Maryland) under award number R01 HL115150. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was supported by Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning(MSIP) (2012027176). This study was also funded, in part, by a generous gift from the Dalio Institute of Cardiovascular Imaging (New York, NY) and the Michael Wolk Foundation (New York, NY). Publisher Copyright: © 2014 Elsevier Ireland Ltd.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: This study sought to determine the correlation between baseline cardiac medications and cardiovascular outcomes in patients with obstructive coronary artery disease (CAD) diagnosed by coronary computed tomographic angiography (CCTA). Methods: 1637 patients (mean age 64.8±10.2 years, 69.6% male) with obstructive CAD from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registry were followed over the course of three years. Obstructive CAD was defined as a ≥50% stenosis in an epicardial vessel. Medications analyzed included statins, aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Using Cox proportional-hazards models, we calculated the hazard ratio (HR) with 95% confidence intervals (95% CIs) for incident major adverse cardiovascular events (MACE), defined as death, acute coronary syndrome, or myocardial infarction. Results: At the time of CCTA, 59%, 54%, 40%, and 46% of patients were using statins, aspirin, beta-blockers, and ACE inhibitors or ARBs, respectively. Statins were associated with a 43% (95% CI=0.38-0.87, p=0.008) lower adjusted risk of MACE. Following adjustment, aspirin, beta-blockers, ACE inhibitors and ARBs did not attenuate the risk of MACE. When restricted to patients with multivessel obstructive CAD, only statins were associated with lower risk of MACE. Conclusion: In patients with obstructive CAD by CCTA, the baseline use of statins was associated with improved clinical outcomes. Other cardiac medications-including aspirin, beta-blockers, ACE inhibitors, and ARBs-were not associated with reduced risk of MACE.

AB - Objective: This study sought to determine the correlation between baseline cardiac medications and cardiovascular outcomes in patients with obstructive coronary artery disease (CAD) diagnosed by coronary computed tomographic angiography (CCTA). Methods: 1637 patients (mean age 64.8±10.2 years, 69.6% male) with obstructive CAD from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) registry were followed over the course of three years. Obstructive CAD was defined as a ≥50% stenosis in an epicardial vessel. Medications analyzed included statins, aspirin, beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Using Cox proportional-hazards models, we calculated the hazard ratio (HR) with 95% confidence intervals (95% CIs) for incident major adverse cardiovascular events (MACE), defined as death, acute coronary syndrome, or myocardial infarction. Results: At the time of CCTA, 59%, 54%, 40%, and 46% of patients were using statins, aspirin, beta-blockers, and ACE inhibitors or ARBs, respectively. Statins were associated with a 43% (95% CI=0.38-0.87, p=0.008) lower adjusted risk of MACE. Following adjustment, aspirin, beta-blockers, ACE inhibitors and ARBs did not attenuate the risk of MACE. When restricted to patients with multivessel obstructive CAD, only statins were associated with lower risk of MACE. Conclusion: In patients with obstructive CAD by CCTA, the baseline use of statins was associated with improved clinical outcomes. Other cardiac medications-including aspirin, beta-blockers, ACE inhibitors, and ARBs-were not associated with reduced risk of MACE.

UR - http://www.scopus.com/inward/record.url?scp=84913557639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913557639&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.11.007

DO - 10.1016/j.atherosclerosis.2014.11.007

M3 - Article

C2 - 25479800

AN - SCOPUS:84913557639

SN - 0021-9150

VL - 238

SP - 119

EP - 125

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -

Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: Results from the multicenter CONFIRM registry

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this